Cosmos Health Inc (COSM) FinancialsCOSMCosmos Health Inc

Cosmos Health Inc (COSM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Wholesale, accounting for 94.2% of total sales, equivalent to $16.89M. Other significant revenue streams include Nutraceutical and pharmaceuticals and Pharma manufacturing. Understanding this composition is critical for investors evaluating how COSM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Cosmos Health Inc maintains a gross margin of 6.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.41%, while the net margin is -32.06%. These profitability ratios, combined with a Return on Equity (ROE) of -104.00%, provide a clear picture of how effectively COSM converts its operational activities into shareholder value.

In the context of the broader market, COSM competes directly with industry leaders such as EYPT and ALGS. With a market capitalization of $30.69M, it holds a significant position in the sector. When comparing efficiency, COSM's gross margin of 6.12% stands against EYPT's 100.00% and ALGS's 100.00%. Such benchmarking helps identify whether Cosmos Health Inc is trading at a premium or discount relative to its financial performance.

Cosmos Health reported a revenue increase of 28% in Q2 2026, reaching $18.99 million, but also a net loss of $6.09 million, indicating financial instability despite growth in sales.